1.07 Adjuvant Sunitinib in RCC, future of EBM with Dr. John Mandrola

OncologyMedicineHealth Policy
Written By Kerrington .

In this episode we discuss the USA FDA's recent approval of sunitinib as the adjuvant treatment for patients with resected renal cell carcinoma who are at high risk of relapse. We also interview cardiologist Dr. John Mandrola on new directions forward for evidence-based medicine.

Kerrington .
Previous

1.08 Hyperprolific authors, NCCN with Jeff Wagner, and Dr. Renee Dversdal on Ultrasounds
Next

1.06 RELEVANCE, Jenny Gill, and Dr. Catherine Livingston of the Oregon Health Authority